Business Context and Reporting Period
This Form 8-K Current Report was filed by Akers Biosciences, Inc. (Ticker: AKER) on September 11, 2020. The report discloses compensatory arrangements for the Company's directors under the 2018 Equity Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity compensation awards and does not contain financial performance data.
Material Changes
The material change reported is the grant of Restricted Stock Units (RSUs) to four directors on September 11, 2020. This follows a comprehensive review of director compensation, noting that prior equity awards to the current board were limited to 5,201 RSUs per director in 2019, with the previous grant occurring in 2017.
Guidance, Outlook, and Management Commentary
- Grant Details:
- Christopher C. Schreiber (Executive Chairman and President): 263,500 RSUs
- Joshua Silverman: 219,000 RSUs
- William White: 219,000 RSUs
- Robert Schroeder: 87,860 RSUs
- Vesting Schedule: 50% of the RSUs vest on the first anniversary of the grant date, and the remaining 50% vest on the second anniversary.
- Acceleration Clauses: RSUs vest immediately upon a change in control (if the director is still serving), termination due to death or disability, or termination by the Company without cause.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2018 Equity Incentive Plan to assess remaining capacity for future grants.
- Confirm the fair market value of the stock on September 11, 2020, to calculate the total compensation expense impact.
- Review the Company's cash position and burn rate, as this filing does not disclose liquidity status.
- Check for any subsequent filings regarding the vesting status or forfeiture of these specific RSUs.